Xenon Pharmaceuticals Inc.'s XEN1101 shows promise in epilepsy with strong phase 2b results and solid financials. Click here ...
Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback